In This Article:
As the German economy faces a forecasted contraction in 2024, recent data highlights challenges such as declining factory orders, though industrial production has shown some resilience. In this climate, growth companies with high insider ownership can present intriguing opportunities for investors seeking alignment between management and shareholder interests.
Top 10 Growth Companies With High Insider Ownership In Germany
| Name | Insider Ownership | Earnings Growth |
| Stemmer Imaging (XTRA:S9I) | 25% | 23.2% |
| Exasol (XTRA:EXL) | 25.3% | 117.1% |
| Deutsche Beteiligungs (XTRA:DBAN) | 39.6% | 54.1% |
| adidas (XTRA:ADS) | 16.6% | 41.8% |
| pferdewetten.de (XTRA:EMH) | 20.6% | 97.9% |
| Alelion Energy Systems (DB:2FZ) | 37.4% | 106.6% |
| Beyond Frames Entertainment (DB:8WP) | 10.8% | 112.2% |
| Friedrich Vorwerk Group (XTRA:VH2) | 18.8% | 24.6% |
| Redcare Pharmacy (XTRA:RDC) | 17.4% | 54.3% |
| Your Family Entertainment (DB:RTV) | 17.3% | 124.4% |
Let's uncover some gems from our specialized screener.
Brockhaus Technologies
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Brockhaus Technologies AG is a private equity firm with a market cap of €291.49 million.
Operations: The company's revenue segments include €37.03 million from Security Technologies and €174.59 million from Financial Technologies.
Insider Ownership: 26.6%
Earnings Growth Forecast: 93% p.a.
Brockhaus Technologies demonstrates significant growth potential with revenue expected to increase by 16.8% annually, outpacing the German market. Despite a current net loss of €6.65 million for H1 2024, profitability is anticipated within three years, exceeding average market growth rates. The company confirmed its revenue guidance for 2024 and 2025, targeting up to €320 million in 2025. Insider ownership remains substantial without recent insider trading activity reported over the past three months.
Redcare Pharmacy
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Redcare Pharmacy NV is an online pharmacy operating in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France with a market cap of €2.92 billion.
Operations: The company generates revenue of €1.74 billion from the DACH region and €391 million internationally.
Insider Ownership: 17.4%
Earnings Growth Forecast: 54.3% p.a.
Redcare Pharmacy's revenue is projected to grow at 17.5% annually, surpassing the German market average. Despite a net loss of €12.07 million for H1 2024, profitability is expected within three years, indicating robust growth potential. The company recently raised its full-year sales guidance to between €2.35 billion and €2.5 billion for 2024, reflecting positive momentum despite past shareholder dilution and significant insider selling over the last quarter without substantial buying activity.